| 1. |
Dahlgren US, Bennet W. ABO-incompatible liver transplantation - A review of the historical background and results. Int Rev Immunol, 2019, 38(3): 118-128.
|
| 2. |
Starzl TE, Koep LJ, Halgrimson CG, et al. Fifteen years of clinical liver transplantation. Gastroenterology, 1979, 77(2): 375-388.
|
| 3. |
Gugenheim J, Samuel D, Reynes M, et al. Liver transplantation across ABO blood group barriers. Lancet, 1990, 336(8714): 519-523.
|
| 4. |
Gordon RD, Iwatsuki S, Esquivel CO, et al. Liver transplantation across ABO blood groups. Surgery, 1986, 100(2): 342-348.
|
| 5. |
Nelson PW, Helling TS, Pierce GE, et al. Successful transplantation of blood group A2 kidneys into non-A recipients. Transplantation, 1988, 45(2): 316-319.
|
| 6. |
Skogsberg U, Breimer ME, Friman S, et al. Adult ABO-incompatible liver transplantation, using A and B donors. Xenotransplantation, 2006, 13(2): 154-159.
|
| 7. |
Kluger MD, Guarrera JV, Olsen SK, et al. Safety of blood group A2-to-O liver transplantation: an analysis of the United Network of Organ Sharing database. Transplantation, 2012, 94(5): 526-531.
|
| 8. |
Farges O, Kalil AN, Samuel D, et al. The use of ABO-incompatible grafts in liver transplantation: a life-saving procedure in highly selected patients. Transplantation, 1995, 59(8): 1124-1133.
|
| 9. |
Reding R, Veyckemans F, de Ville de Goyet J, et al. ABO-incompatible orthotopic liver allografting in urgent indications. Surg Gynecol Obstet, 1992, 174(1): 59-64.
|
| 10. |
Egawa H, Oike F, Buhler L, et al. Impact of recipient age on outcome of ABO-incompatible living-donor liver transplantation. Transplantation, 2004, 77(3): 403-411.
|
| 11. |
Cheng CH, Lee CF, Wang YC, et al. ABo-incompatible liver transplantation: state of art and future perspectives. Curr Pharm Des, 2020, 26(28): 3406-3417.
|
| 12. |
Takahashi K, Saito K. ABO-incompatible kidney transplantation. Transplant Rev (Orlando), 2013, 27(1): 1-8.
|
| 13. |
Ueda D, Yoshizawa A, Kaneshiro M, et al. Low titers of antidonor ABO antibodies after ABO-incompatible living donor liver transplantation: A long-term follow-up study. Transplant Direct, 2018, 5(1): e420.
|
| 14. |
Stegall MD, Gloor JM. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr Opin Organ Transplant, 2010, 15(1): 8-10.
|
| 15. |
Garcia de Mattos Barbosa M, Cascalho M, Platt JL. Accommodation in ABO-incompatible organ transplants. Xenotransplantation, 2018, 25(3): e12418.
|
| 16. |
Platt JL, Garcia de Mattos Barbosa M, Cascalho M. The five dimensions of B cell tolerance. Immunol Rev, 2019, 292(1): 180-193.
|
| 17. |
Hsu SC, Thorat A, Jeng LB, et al. ABO-incompatible living donor liver transplantation with reduced rituximab dose: A retrospective analysis of 65 patients - Can we fast-track liver transplant surgery and improve long-term survival? Ann Transplant, 2020, 25: e923502.
|
| 18. |
Bajpai M, Kakkar B, Gupta S, et al. Cascade plasmapheresis as a desensitization strategy for patients undergoing ABO incompatible living donor liver transplantation (ABOi LDLT): A single center experience. Transfus Apher Sci, 2019, 58(4): 442-446.
|
| 19. |
Tanabe M, Shimazu M, Wakabayashi G, et al. Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation, 2002, 73(12): 1959-1961.
|
| 20. |
Tanabe M, Kawachi S, Obara H, et al. Current progress in ABO-incompatible liver transplantation. Eur J Clin Invest, 2010, 40(10): 943-949.
|
| 21. |
Egawa H, Teramukai S, Haga H, et al. Present status of ABO-incompatible living donor liver transplantation in Japan. Hepatology, 2008, 47(1): 143-152.
|
| 22. |
Egawa H. Challenge to ABO blood type barrier in living donor liver transplantation. Hepatobiliary Pancreat Dis Int, 2020, 19(4): 342-348.
|
| 23. |
Egawa H, Teramukai S, Haga H, et al. Impact of rituximab desensitization on blood-type-incompatible adult living donor liver transplantation: a Japanese multicenter study. Am J Transplant, 2014, 14(1): 102-114.
|
| 24. |
Lee EC, Kim SH, Shim JR, et al. A comparison of desensitization methods: Rituximab with/without plasmapheresis in ABO-incompatible living donor liver transplantation. Hepatobiliary Pancreat Dis Int, 2018, 17(2): 119-125.
|
| 25. |
Zhou W, Ohdan H, Asahara T. Calcineurin inhibitors block B-1 cell differentiation: the relevance to immunosuppressive treatment in ABO-incompatible transplantation. Transplant Proc, 2005, 37(4): 1808-1811.
|
| 26. |
Oh J, Kim JM. Immunologic strategies and outcomes in ABO-incompatible living donor liver transplantation. Clin Mol Hepatol, 2020, 26(1): 1-6.
|
| 27. |
Lee SD, Kim SH, Kong SY, et al. ABO-incompatible living donor liver transplantation without graft local infusion and splenectomy. HPB (Oxford), 2014, 16(9): 807-813.
|
| 28. |
Montgomery RA, Loupy A, Segev DL. Antibody-mediated rejection: New approaches in prevention and management. Am J Transplant, 2018, 18(Suppl 3): 3-17.
|
| 29. |
Cacciarelli TV, So SK, Lim J, et al. A reassessment of ABO incompatibility in pediatric liver transplantation. Transplantation, 1995, 60(7): 757-760.
|
| 30. |
Honda M, Sugawara Y, Kadohisa M, et al. Long-term outcomes of ABO-incompatible pediatric living donor liver transplantation. Transplantation, 2018, 102(10): 1702-1709.
|
| 31. |
Fong SW, Qaqundah BY, Taylor WF. Developmental patterns of ABO isoagglutinins in normal children correlated with the effects of age, sex, and maternal isoagglutinins. Transfusion, 1974, 14(6): 551-559.
|
| 32. |
Rahfeld P, Withers SG. Toward universal donor blood: Enzymatic conversion of A and B to O type. J Biol Chem, 2020, 295(2): 325-334.
|
| 33. |
Jeyakanthan M, Meloncelli PJ, Zou L, et al. ABH-glycan microarray characterizes ABO subtype antibodies: Fine specificity of immune tolerance after ABO-incompatible transplantation. Am J Transplant, 2016, 16(5): 1548-1558.
|
| 34. |
Jeyakanthan M, Tao K, Zou L, et al. Chemical basis for qualitative and quantitative differences between ABO blood groups and subgroups: Implications for organ transplantation. Am J Transplant, 2015, 15(10): 2602-2615.
|
| 35. |
Abegaz SB. Human ABO blood groups and their associations with different diseases. Biomed Res Int, 2021, 2021: 6629060.
|
1/5
WeChat